NHL Cyberfamily

Non-Hodgkin's lymphoma support

 

American society of hematology 2013



 

Lymphoma abstracts from the American Society of Hematology (ASH) 2013 convention in New Orleans

ASH abstract home page

Click on any of the categories below to get a list of abstracts on that topic from the 2013 ASH convention. There is an outstanding amount of good information in these abstracts.

622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster I

622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster II

622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster III

623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster I

623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster II

623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster III

624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I

624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II

624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III

625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster I

625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster II

625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster III

701. Experimental Transplantation: Basic Biology, Engraftment and Disease Activity: Poster I

701. Experimental Transplantation: Basic Biology, Engraftment and Disease Activity: Poster II

701. Experimental Transplantation: Basic Biology, Engraftment and Disease Activity: Poster III

702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster I

702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster II

702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster III

703. Adoptive Immunotherapy

703. Adoptive Immunotherapy: Poster I

703. Adoptive Immunotherapy: Poster II

703. Adoptive Immunotherapy: Poster III

721. Clinical Allogeneic Transplantation - Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Poster I

721. Clinical Allogeneic Transplantation - Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Poster II

721. Clinical Allogeneic Transplantation - Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Poster III

722. Clinical Allogeneic Transplantation - Acute and Chronic GVHD, Immune Reconstitution: Poster I

722. Clinical Allogeneic Transplantation - Acute and Chronic GVHD, Immune Reconstitution: Poster II

722. Clinical Allogeneic Transplantation - Acute and Chronic GVHD, Immune Reconstitution: Poster III

723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Poster II

723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Poster III

723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster I

731. Clinical Allogeneic and Autologous Transplantation - Results: Poster I

731. Clinical Allogeneic and Autologous Transplantation - Results: Poster II

 

You can also search for any specific word or drug or title from the 2013 abstracts using the search box below. Your search will be limited to the 2013 ASH abstracts.

 


web counter


website
statistics